Caliway Biopharmaceuticals Co (TPE:6919) ROCE %: -9.46% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6919 Caliway Biopharmaceuticals Co Ltd TPE:6919
55 GF Score
Price NT$91.20
GF Value NT$59.03
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Caliway Biopharmaceuticals Co ROCE %?

Caliway Biopharmaceuticals Co TPE:6919 -3.80% 55 ROCE % is -9.46% as of Jun. 2026. GuruFocus rates TPE:6919 with a GF Score™ of 55/100 and a GF Value™ of NT$59.03 (Significantly Overvalued). The stock has 8 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Caliway Biopharmaceuticals Co's annualized ROCE % for the quarter that ended in Jun. 2026 was -9.46%.

Caliway Biopharmaceuticals Co  (TPE:6919) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Caliway Biopharmaceuticals Co ROCE % Related Terms

Caliway Biopharmaceuticals Co ROCE % Historical Data

* Premium members only.

The historical data trend for Caliway Biopharmaceuticals Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Caliway Biopharmaceuticals Co ROCE % Chart

Caliway Biopharmaceuticals Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -52.97 -30.73 -19.77 -8.74 -3.67

Caliway Biopharmaceuticals Co Quarterly Data
Dec19 Dec20 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.48 -0.33 3.41 -4.57 -9.46
TPE:6919
55GF Score
Caliway Biopharmaceuticals Co Ltd TPE:6919
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Caliway Biopharmaceuticals Co ROCE % Calculation

Caliway Biopharmaceuticals Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-351.762/( ( (9770.507 - 52.744) + (9474.106 - 45.494) )/ 2 )
=-351.762/( (9717.763+9428.612)/ 2 )
=-351.762/9573.1875
=-3.67 %

Caliway Biopharmaceuticals Co's ROCE % of for the quarter that ended in Jun. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=-888.748/( ( (9536.63 - 111.245) + (9430.858 - 69.932) )/ 2 )
=-888.748/( ( 9425.385 + 9360.926 )/ 2 )
=-888.748/9393.1555
=-9.46 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -9.46% mean?
Caliway Biopharmaceuticals Co (TPE:6919) has a ROCE % of -9.46% as of Jun. 2026.
Is Caliway Biopharmaceuticals Co's ROCE % too high?
Caliway Biopharmaceuticals Co's current ROCE % is -9.46%. Overall, Caliway Biopharmaceuticals Co has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Caliway Biopharmaceuticals Co's ROCE % compare to VRTX and REGN?
Caliway Biopharmaceuticals Co's ROCE % of -9.46% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Caliway Biopharmaceuticals Co's current ROCE % is -9.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caliway Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Caliway Biopharmaceuticals Co (TPE:6919) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$59.03, compared to a current price of NT$91.20 — trading 54.5% above its estimated fair value. The current ROCE % is -9.46%. Caliway Biopharmaceuticals Co's overall GF Score™ is 55/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Caliway Biopharmaceuticals Co (TPE:6919), the current ROCE % is -9.46% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Caliway Biopharmaceuticals Co (TPE:6919) Overvalued in 2026?

Based on GuruFocus' analysis, Caliway Biopharmaceuticals Co stock appears to be overvalued. The current stock price of NT$91.20 is trading 54.5% above its estimated GF Value™ of NT$59.03. GuruFocus considers Caliway Biopharmaceuticals Co to be Significantly Overvalued.

Key valuation signals for TPE:6919:

  • ROCE %: -9.46%
  • GF Value™: NT$59.03 vs. price of NT$91.20 (54.5% above fair value)
  • GF Score™: 55/100 with 8 warning signs

No single metric tells the full story. See the TPE:6919 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Caliway Biopharmaceuticals Co Business Description

Address No.99, Section 1, Xintai 5th Road, 32rd Floor-9, Xizhi District, New Taipei City, TWN, 221
Caliway Biopharmaceuticals Co Ltd specializes in the development of new drugs for aesthetic medicine and chronic inflammation. The group has one operating segment, which is Healthy Food, and others.
55GF Score

Get the complete analysis for TPE:6919

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$91.20
Price
NT$59.03
GF Value